Healis Partnerns with Massachusetts Hospital for Neuroscience Research

Healis Partnerns with Massachusetts Hospital for Neuroscience Research

By, Admin 28 March 2024

Healis Therapeutics inks collaboration with Massachusetts General Hospital to advance clinical-stage neuroscience research

Overview

Healis Therapeutics, a neurotherapeutics company advancing the treatment of neuropsychiatric and neurodegenerative disease, announced that it has entered into a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Focus of Collab

  • The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions, including major depressive disorder (MDD), PTSD, and social anxiety disorder (SAD).
  • One of Healis’ strategic priorities is developing the research of Dr. Eric Finzi, who first discovered the efficacy of BoNT/A neuromodulators for neuropsychiatric disorders. “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, co-founder of Healis Therapeutics. ""We are thrilled to work with the world’s leading psychiatry researchers, bringing deep clinical expertise to Healis Therapeutics’ upcoming trial.”

A Revolutionary Clinical Programme

  • Healis Therapeutics’ clinical programme in BoNT/A for neuropsychiatry alone has the potential to transform care for what the World Health Organization (WHO) estimates at 280 million patients suffering from major depressive disorder globally. “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, head of clinical trials at Healis Therapeutics. Erik previously worked with Harvard T Chan School of Public Health and alongside major biopharma companies Merck, Roche, Bristol Myers Squibb, Glaxo-Smith Klein, and others.
  • “We are thrilled to be at the forefront of this field of research and could not have hoped for a better research partner than Mass. General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, co-founder of Healis Therapeutics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!